{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T14:25:37Z","timestamp":1768141537237,"version":"3.49.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>With the shortage of bacillus Calmette\u2013Gue\u0301rin (BCG) vaccine, it is important to find an alternative to BCG instillation, which is the most commonly used adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC) patients after transurethral resection of bladder tumor treatment (TURBt) to delay tumor recurrence. Hyperthermia intravesical chemotherapy (HIVEC) with mitomycin C (MMC) is a potential treatment choice. We aim to compare HIVEC with BCG instillation for the preventive efficacy of bladder tumor recurrence and progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A network meta-analysis (NMA) was taken with MMC instillation and TURBt as the attached comparators. Randomized controlled trials (RCTs) with NIMBC patients after TURBt were included. Articles with pure BCG unresponsive patients and combined therapies were excluded. The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO, CRD42023390363).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>It was found that HIVEC had a non-significant 22% relative reduction in bladder tumor recurrence compared with BCG instillation [HIVEC vs. BCG: HR 0.78, 95% credible interval (CrI) 0.55\u20131.08] and a nonsignificant higher risk of bladder tumor progression (BCG vs. HIVEC: HR 0.77, 95% CrI 0.22\u20133.03).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>HIVEC is a potential alternative to BCG, and it is expected to be the standard therapy for NMIBC patients after TURBt during the global shortage of BCG.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p>PROSPERO identifier, CRD42023390363<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1164932","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T06:10:05Z","timestamp":1683871805000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Hyperthermia intravesical chemotherapy acts as a promising alternative to bacillus Calmette\u2013Gu\u00e9rin instillation in non-muscle-invasive bladder cancer: a network meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Na","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Yao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Xuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Zhou","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing-Yu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Yang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao-Dong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-Dong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao-Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2018.06.018","article-title":"Manufacturing and the market: rationalizing the shortage of bacillus calmette-gu\u00e9rin","volume":"4","author":"Bandari","year":"2018","journal-title":"Eur Urol Focus"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin c versus bacillus calmette-gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2021.775527","article-title":"Intravesical chemohyperthermia vs. bacillus calmette-guerin instillation for intermediate- and high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"8","author":"Zhao","year":"2021","journal-title":"Front Surg"},{"key":"B6","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1471-2288-10-54","article-title":"Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial","volume":"10","author":"Woods","year":"2010","journal-title":"BMC Med Res Methodol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"B9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","article-title":"Radiofrequency-induced thermo-chemotherapy effect versus a second course of bacillus calmette-gu\u00e9rin or institutional standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance bacillus calmette-gu\u00e9rin therapy (HYMN): a phase III, open-label, randomised controlled trial","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","article-title":"Recirculating hyperthermic intravesical chemotherapy with mitomycin c (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial","volume":"40","author":"Guerrero-Ramos","year":"2022","journal-title":"World J Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09654.x","article-title":"Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-c alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC)","volume":"107","author":"Colombo","year":"2011","journal-title":"BJU Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.08.003","article-title":"Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): a phase 2, open-label, randomised controlled trial","author":"Tan","year":"2022","journal-title":"Eur Urology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2022.10.008","article-title":"Hyperthermic mitomycin c in intermediate-risk non-muscle-invasive bladder cancer: results of the HIVEC-1 trial","volume":"6","author":"Angulo","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00374-4","article-title":"Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression","volume":"52","author":"Smits","year":"1998","journal-title":"Urology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(01)65853-1","article-title":"A randomized prospective study comparing long-term intravesical instillations of mitomycin c and bacillus calmette-guerin in patients with superficial bladder carcinoma","volume":"156","author":"Lundholm","year":"1996","journal-title":"J Urol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(93)90102-L","article-title":"A randomised prospective study comparing intravesical instillations of mitomycin-c, BCG-tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder","volume":"29","author":"Witjes","year":"1993","journal-title":"Eur J Cancer Part A: Gen Topics"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.6.1404","article-title":"Intravesical bacillus calmette-gu\u00e9rin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial","volume":"13","author":"Herr","year":"1995","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1997.00431.x","article-title":"Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome","volume":"80","author":"Herr","year":"1997","journal-title":"Br J Urol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","article-title":"Bacillus calmette-guerin immunotherapy of superficial bladder cancer","volume":"124","author":"Lamm","year":"1980","journal-title":"J Urol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000471653","article-title":"Intravesical chemotherapy (mitomycin c) versus immunotherapy (bacillus calmette-gu\u00e9rin) in superficial bladder cancer","volume":"20","author":"Rintala","year":"1991","journal-title":"Eur Urol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-4295(98)00212-x","article-title":"Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille calmette-Gu\u00e9rin-RIVM and mitomycin c in superficial bladder cancer. EORTC GU group and the Dutch south East cooperative urological group. European organisation for research and treatment of cancer genito-urinary tract cancer collaborative group","volume":"52","author":"Witjes","year":"1998","journal-title":"Urology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.02.063","article-title":"Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus calmette-gu\u00e9rin (BCG) in patients with non-muscle-invasive bladder carcinoma","volume":"52","author":"Friedrich","year":"2007","journal-title":"Eur Urol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2006.06706.x","article-title":"Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-c and bacillus calmette-gu\u00e9rin in patients with high-risk bladder cancer","volume":"99","author":"G\u00e5rdmark","year":"2007","journal-title":"BJU Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.04.062","article-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus calmette-guerin (27 mg) versus very low-dose bacillus calmette-guerin (13.5 mg) versus mitomycin c","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-008-1671-z","article-title":"[Comparison of the effectiveness between long-term instillation of mitomycin c and short-term prophylaxis with MMC or bacille calmette-guerin. study of patients with non-muscle-invasive urothelial cancer of the urinary bladder]. [German]","volume":"47","author":"Isbarn","year":"2008","journal-title":"Urologe"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/BF00256725","article-title":"Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer","author":"Niijima","year":"1983","journal-title":"Cancer Chemother Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/BF00262491","article-title":"Prophylactic intravesical instillation therapy with adriamycin and mitomycin c in patients with superficial bladder cancer","author":"Tsushima","year":"1987","journal-title":"Cancer Chemother Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"997","DOI":"10.5980\/jpnjurol1989.81.997","article-title":"[Intravesical bacillus calmette-guerin (BCG) in the treatment of superficial bladder cancer. prospective randomized study for prophylactic effect]","volume":"81","author":"Yamamoto","year":"1990","journal-title":"Nihon Hinyokika Gakkai Zasshi"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-199609000-00032","article-title":"A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin c versus transurethral resection plus bacillus calmette-guerin. participating clinics","volume":"156","author":"Krege","year":"1996","journal-title":"J Urol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-2042.2001.00286.x","article-title":"Prophylactic intravesical instillation of mitomycin c and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study","volume":"8","author":"Sakamoto","year":"2001","journal-title":"Int J Urol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-011-0691-2","article-title":"Long-term experience with early single mitomycin c instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial","volume":"29","author":"De Nunzio","year":"2011","journal-title":"World J Urol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/BF00262495","article-title":"Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. prospective, randomized, controlled studies of the Japanese urological cancer research group","author":"Akaza","year":"1987","journal-title":"Cancer Chemother Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/S0022-5347(17)41300-0","article-title":"Intravesical mitomycin c instillation as a prophylactic treatment of superficial bladder tumor","volume":"141","author":"Kim","year":"1989","journal-title":"J Urol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37707-8","article-title":"A low dose bacillus calmette-guerin regimen in superficial bladder cancer therapy: is it effective","volume":"146","author":"Pagano","year":"1991","journal-title":"J Urol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930901)72:5<1749::aid-cncr2820720539>3.0.co;2-8","article-title":"Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus calmette-gu\u00e9rin. a controlled prospective study on the prophylaxis of superficial bladder cancer","volume":"72","author":"Melekos","year":"1993","journal-title":"Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)67606-7","article-title":"A randomized study of intravesical mitomycin c, bacillus calmette-guerin tice and bacillus calmette-guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder","volume":"153","author":"Vegt","year":"1995","journal-title":"J Urol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/1078-1439(95)00041-F","article-title":"Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin c chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study","volume":"1","author":"Lamm","year":"1995","journal-title":"Urol Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-199604000-00023","article-title":"The effect of intravesical mitomycin c on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up","volume":"155","author":"Tolley","year":"1996","journal-title":"J Urol"},{"key":"B39","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-5347(01)61607-0","article-title":"5-year followup of a randomized prospective study comparing mitomycin c and bacillus calmette-guerin in patients with superficial bladder carcinoma. Swedish-Norwegian bladder cancer study group","volume":"161","author":"Malmstr\u00f6m","year":"1999","journal-title":"J Urol"},{"key":"B40","article-title":"A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy","volume":"80","author":"Mangiarotti","year":"2008","journal-title":"Arch Ital Urol Androl"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.04.009","article-title":"Long-term efficacy of maintenance bacillus calmette-gu\u00e9rin versus maintenance mitomycin c instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up","volume":"56","author":"J\u00e4rvinen","year":"2009","journal-title":"Eur Urol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"113059","DOI":"10.1016\/j.ecoenv.2021.113059","article-title":"The comprehensive analysis based study of perfluorinated compounds-environmental explanation of bladder cancer progression","volume":"229","author":"Ye","year":"2022","journal-title":"Ecotoxicol Environ Saf"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.18632\/aging.103620","article-title":"Early-life exposure to bisphenol a and reproductive-related outcomes in rodent models: a systematic review and meta-analysis","volume":"12","author":"Ren","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s11356-021-14970-8","article-title":"Pharmacophore based in silico study with laboratory verification-environmental explanation of prostate cancer recurrence","volume":"28","author":"Zhang","year":"2021","journal-title":"Environ Sci pollut Res Int"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1038\/s41598-022-07070-1","article-title":"AC010973.2 promotes cell proliferation and is one of six stemness-related genes that predict overall survival of renal clear cell carcinoma","volume":"12","author":"Liu","year":"2022","journal-title":"Sci Rep"},{"key":"B46","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","article-title":"Recirculating hyperthermic intravesical chemotherapy with mitomycin c (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial","volume":"40","author":"Guerrero-Ramos","year":"2022","journal-title":"World J Urol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"76.e9","DOI":"10.1016\/j.urolonc.2020.07.003","article-title":"Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia","volume":"39","author":"Gonz\u00e1lez-Padilla","year":"2021","journal-title":"Urol Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4103\/UA.UA_139_20","article-title":"Comparing adverse effects, short term outcomes, and cost implications of hyperthermic intravesical chemotherapy with mitomycin-c and intravesical bacillus calmette-guerin instillation (Moscow-I strain) in the management of intermediate and high-risk nonmuscle invasive bladder cancer","volume":"13","author":"Thyavihally","year":"2021","journal-title":"Urol Ann"},{"key":"B49","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.3390\/jcm10215105","article-title":"Long-term experience with hyperthermic chemotherapy (HIVEC) using mitomycin-c in patients with non-muscle invasive bladder cancer in Spain","volume":"10","author":"Plata","year":"2021","journal-title":"J Clin Med"},{"key":"B50","article-title":"Hyperthermia as a treatment for bladder cancer","volume":"24","author":"Rampersaud","year":"2010","journal-title":"Oncol (Williston Park)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000146274.85012.e1","article-title":"Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study","volume":"173","author":"van der Heijden","year":"2005","journal-title":"J Urol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.5173\/ceju.2020.0148","article-title":"Outcomes and complications of hyperthermic IntraVesical chemotherapy using mitomycin c or epirubicin for patients with non-muscle invasive bladder cancer after bacillus calmette-gu\u00e9rin treatment failure","volume":"73","author":"Chiancone","year":"2020","journal-title":"Cent Eur J Urol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3513","article-title":"Efficacy of intravesical therapies on the prevention of recurrence and progression of non-muscle-invasive bladder cancer: a systematic review and network meta-analysis","volume":"9","author":"Lu","year":"2020","journal-title":"Cancer Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-021-03264-6","article-title":"T1 bladder carcinoma with variant histology: pathological features and clinical significance","volume":"480","author":"Lopez-Beltran","year":"2022","journal-title":"Virchows Arch"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15984","article-title":"Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy","author":"Claps","year":"2023","journal-title":"BJU Int"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-022-03958-9","article-title":"Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration","volume":"40","author":"Lonati","year":"2022","journal-title":"World J Urol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.07.019","article-title":"Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer","volume":"40","author":"Pijpers","year":"2022","journal-title":"Urol Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-015-1595-3","article-title":"Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study","volume":"34","author":"Soria","year":"2016","journal-title":"World J Urol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"300.e15","DOI":"10.1016\/j.urolonc.2020.09.016","article-title":"Cystectomy outcomes in patients who have failed radiofrequency-induced thermo-chemotherapeutic effect mitomycin-c (RITE-MMC) treatment for high-risk non-muscle invasive bladder cancer (HRNMIBC)-does it complicate surgery and adversely impact oncological outcome","volume":"39","author":"Sri","year":"2021","journal-title":"Urol Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1164932\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T06:10:12Z","timestamp":1683871812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1164932\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":59,"alternative-id":["10.3389\/fonc.2023.1164932"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1164932","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"article-number":"1164932"}}